Tirzepatide Real-World Safety: FAERS Database Analysis of Adverse Events
Retrospective analysis of FDA FAERS data identifies real-world safety concerns with tirzepatide beyond clinical trial reporting, including GI events and hypoglycemia patterns.
Quick Facts
What This Study Found
Retrospective analysis of FDA FAERS data identifies real-world safety concerns with tirzepatide beyond clinical trial reporting, including GI events and hypoglycemia patterns.
Key Numbers
FAERS reports from 2022 to Q1 2025 analyzed using proportional reporting ratio and related disproportionality methods.
How They Did This
Methodology detailed in publication.
Why This Research Matters
Relevant to expanding peptide-based therapeutic applications.
The Bigger Picture
Contributes to the growing evidence for peptide therapeutics.
What This Study Doesn't Tell Us
Limitations in publication.
Questions This Raises
- ?Long-term implications?
- ?Comparison to existing evidence?
- ?Next research steps?
Trust & Context
- Key Stat:
- Key finding Retrospective analysis of FDA FAERS data identifies real-world safety concerns with tirzepatide beyo
- Evidence Grade:
- Based on study design in publication.
- Study Age:
- Published in 2025.
- Original Title:
- Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025).
- Published In:
- Healthcare (Basel, Switzerland), 13(18) (2025)
- Authors:
- Almansour, Hadi A, Thaibah, Hilal A, Alfarhan, Moaddey, Al-Qahtani, Saeed A, Khardali, Amani A, Alshammari, Thamir M
- Database ID:
- RPEP-09881
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Retrospective analysis of FDA FAERS data identifies real-world safety concerns with tirzepatide beyond clinical trial reporting, including GI events and hypoglycemia patterns.
How reliable?
Consult publication and healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09881APA
Almansour, Hadi A; Thaibah, Hilal A; Alfarhan, Moaddey; Al-Qahtani, Saeed A; Khardali, Amani A; Alshammari, Thamir M. (2025). Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025).. Healthcare (Basel, Switzerland), 13(18). https://doi.org/10.3390/healthcare13182259
MLA
Almansour, Hadi A, et al. "Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025).." Healthcare (Basel, 2025. https://doi.org/10.3390/healthcare13182259
RethinkPeptides
RethinkPeptides Research Database. "Real-World Safety Concerns of Tirzepatide: A Retrospective A..." RPEP-09881. Retrieved from https://rethinkpeptides.com/research/almansour-2025-realworld-safety-concerns-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.